Effect of Breathing Techniques on Migraine Attacks and Severity
9 de setembro de 2022 atualizado por: Oğulcan Çöme, Dokuz Eylul University
The Effect of Breathing Techniques on Attack Frequency and Severity in Migraine-like Headaches-randomised Control Trial: Study Protocol for a Cluster Randomised Controlled Trial
Background:
Migraine is a very common neurobiological disorder caused by increased excitability of the Central Nervous System. It is among the causes of the highest morbidity worldwide. Migraine has considerable economic and social impact ; affects the quality of life of patients and disrupts work life, social activities and family life. To decrease the frequency and severity of migraine attacks may be the first goal than treating the attacks.
The study was designed as a Parallel Group, Add on, Randomized Controlled Experiment in order to observe the effects of breathing techniques on migraine-like headaches, frequency and severity.
Methods:
Participants will be divided into 2 parallel arms, intervention and control (treatment as usual). Cluster randomization will be performed to prevent intergroup contamination. Breathing techniques will be taught to the intervention group by the researcher. Both groups will continue to use pharmacotherapy for migraine. Both groups will be evaluated with migraine disability level (MIDAS) at the beginning and end of the study. The primary output of the study is to evaluate the effect of breathing techniques on the frequency and severity of attacks in migraine-like headaches. The secondary output is to evaluate the effect of breathing techniques on the MIDAS level.
Discussion:
The results of the study will provide information about the effect of breathing techniques on migraine-like headaches. The results of this study will contribute to the literature, since migraine is among the chronic diseases and pharmacotherapy options are limited.
Visão geral do estudo
Status
Ainda não está recrutando
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Antecipado)
86
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: ogulcan come, MD
- Número de telefone: 00905398612323
- E-mail: ogulcan.come@deu.edu.tr
Estude backup de contato
- Nome: azize dilek guldal, proff
- Número de telefone: +905322944377
- E-mail: guldal.dilek@gmail.com
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 50 anos (Adulto)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Are 18-50 Age
- Have a computer and/or smart phone
- Have an internet connection that can be used at home and at work (with a computer or smart phone)
- Are volunteer to participate in the research
- Have Frequency of attacks less than 3 months
- Fulfil diagnostic criteria of migraine like headaches
Exclusion Criteria:
- Severe anatomical defect in the airway
- Pregnancy
- Having any diagnosed psychiatric disease
- Using psychiatric medication
- Having speech and hearing problems
- Having any chronic disease which may be worsening by taking deep breath
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: breathing techniques
The patients in the intervention group will be taught and practiced breathing technique.
Breathing techniques will be taught face-to-face by the researcher to the patients in the intervention group.
The participant will breathe through one nostril at a natural rate and depth, while the other nostril will be closed with the thumb or forefinger.
After the act of breathing, it will open the closed nostril, close the open nostril and breathe naturally.
As explained later, they will continue the cycle with the act of breathing.
This process is described as a loop.
|
Intervention will be daily use of breathing techniques thought by the researcher as explained in detail in arm/group descriptions
|
|
Sem intervenção: treatment as usual
The control group will continue his/her usual treatment as advised by the physician.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Determining effects of breathing techniques on migraine like headaches frequency and intensity with "migraine disability assessment " (MIDAS) questionnaire.
Prazo: Three months
|
The MIDAS is a self-administered tool to assess migraine-related disability over the previous 3 months .
The questionnaire comprises seven questions in total.
Three questions assess the number of missed days due to headache.
Two questions assess the number of additional days with limited productivity.
The total MIDAS score is the sum of the days given as response to these five questions.
The total score ranges from 0 to 90 and is used to categorize patients in disability grades I to IV.
A higher score means more severe disability.Two additional questions measure headache frequency and average pain intensity.
Frequency is noted as the number of days in the previous 3 months on which the patient experienced migraine.
Intensity is noted as the average pain intensity of these episodes on a scale of 1-10.
These two items are not taken into account when estimating the total MIDAS score.
|
Three months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Determining effects of breathing techniques to "migraine disability assessment " (MIDAS) scores of migraine patients.
Prazo: Three months
|
The MIDAS is a self-administered tool to assess migraine-related disability over the previous 3 months .
The questionnaire comprises seven questions in total.
Three questions assess the number of missed days due to headache.
Two questions assess the number of additional days with limited productivity.
The total MIDAS score is the sum of the days given as response to these five questions.
The total score ranges from 0 to 90 and is used to categorize patients in disability grades I to IV.
A higher score means more severe disability.Two additional questions measure headache frequency and average pain intensity.
Frequency is noted as the number of days in the previous 3 months on which the patient experienced migraine.
Intensity is noted as the average pain intensity of these episodes on a scale of 1-10.
These two items are not taken into account when estimating the total MIDAS score.
|
Three months
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: ogulcan D come, MD, Dokuz Eylul University Medical School
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Publicações Gerais
- Campbell MJ, Donner A, Klar N. Developments in cluster randomized trials and Statistics in Medicine. Stat Med. 2007 Jan 15;26(1):2-19. doi: 10.1002/sim.2731.
- Campbell MK, Elbourne DR, Altman DG; CONSORT group. CONSORT statement: extension to cluster randomised trials. BMJ. 2004 Mar 20;328(7441):702-8. doi: 10.1136/bmj.328.7441.702. No abstract available.
- Bernardi L, Spadacini G, Bellwon J, Hajric R, Roskamm H, Frey AW. Effect of breathing rate on oxygen saturation and exercise performance in chronic heart failure. Lancet. 1998 May 2;351(9112):1308-11. doi: 10.1016/S0140-6736(97)10341-5.
- Russo MA, Santarelli DM, O'Rourke D. The physiological effects of slow breathing in the healthy human. Breathe (Sheff). 2017 Dec;13(4):298-309. doi: 10.1183/20734735.009817.
- Roberts C, Roberts SA. Design and analysis of clinical trials with clustering effects due to treatment. Clin Trials. 2005;2(2):152-62. doi: 10.1191/1740774505cn076oa.
- Silberstein SD. Migraine. Lancet. 2004 Jan 31;363(9406):381-91. doi: 10.1016/S0140-6736(04)15440-8.
- Burch R, Rizzoli P, Loder E. The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. Headache. 2018 Apr;58(4):496-505. doi: 10.1111/head.13281. Epub 2018 Mar 12.
- Ciarambino T, Sansone G, Menna G, Para O, Signoriello G, Leoncini L, Giordano M. Oxygen Therapy in Headache Disorders: A Systematic Review. Brain Sci. 2021 Mar 17;11(3):379. doi: 10.3390/brainsci11030379.
- Bennett MH, French C, Schnabel A, Wasiak J, Kranke P. Normobaric and hyperbaric oxygen therapy for migraine and cluster headache. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005219. doi: 10.1002/14651858.CD005219.pub2.
- Singhal AB, Maas MB, Goldstein JN, Mills BB, Chen DW, Ayata C, Kacmarek RM, Topcuoglu MA. High-flow oxygen therapy for treatment of acute migraine: A randomized crossover trial. Cephalalgia. 2017 Jul;37(8):730-736. doi: 10.1177/0333102416651453. Epub 2016 May 20.
- Matera DV, Smith B, Lam B. Revisiting the expanded use of hyperbaric oxygen therapy for treatment of resistant migraines. Med Gas Res. 2019 Oct-Dec;9(4):238-240. doi: 10.4103/2045-9912.273963.
- Bilo G, Revera M, Bussotti M, Bonacina D, Styczkiewicz K, Caldara G, Giglio A, Faini A, Giuliano A, Lombardi C, Kawecka-Jaszcz K, Mancia G, Agostoni P, Parati G. Effects of slow deep breathing at high altitude on oxygen saturation, pulmonary and systemic hemodynamics. PLoS One. 2012;7(11):e49074. doi: 10.1371/journal.pone.0049074. Epub 2012 Nov 12.
- Spatenkova V, Bednar R, Oravcova G, Melichova A, Kuriscak E. Yogic breathing in hypobaric environment: breathing exercising and its effect on hypobaric hypoxemia and heart rate at 3,650-m elevation. J Exerc Rehabil. 2021 Aug 23;17(4):270-278. doi: 10.12965/jer.2142324.162. eCollection 2021 Aug.
- Moher D, Jones A, Lepage L; CONSORT Group (Consolidated Standards for Reporting of Trials). Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA. 2001 Apr 18;285(15):1992-5. doi: 10.1001/jama.285.15.1992.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Antecipado)
1 de novembro de 2022
Conclusão Primária (Antecipado)
1 de abril de 2023
Conclusão do estudo (Antecipado)
1 de julho de 2023
Datas de inscrição no estudo
Enviado pela primeira vez
6 de setembro de 2022
Enviado pela primeira vez que atendeu aos critérios de CQ
9 de setembro de 2022
Primeira postagem (Real)
13 de setembro de 2022
Atualizações de registro de estudo
Última Atualização Postada (Real)
13 de setembro de 2022
Última atualização enviada que atendeu aos critérios de controle de qualidade
9 de setembro de 2022
Última verificação
1 de setembro de 2022
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 7201
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .